The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Share News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 50.20
Bid: 49.90
Ask: 50.20
Change: 1.60 (3.29%)
Spread: 0.30 (0.601%)
Open: 48.45
High: 51.10
Low: 47.20
Prev. Close: 48.60
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IP Group Net Asset Value Slides 6% As Portfolio Value Declines

Wed, 11th Mar 2020 09:04

(Alliance News) - IP Group PLC on Wednesday reported a drop in hard net asset value for 2019 due to a reduction in the fair value of its portfolio.

Also on Wednesday the London-based investor in technology companies announced that Non-Executive Director Jonathan Brooks has stepped down from his role with effect on Tuesday. Brooks has been in the role for nine years since 2011.

As at December 31, IP's hard net asset value per share 108 pence per share, down 6.1% from 115p on the same date a year before.

At the end of 2019, the group's fair value of its portfolio fell by 7.1% to GBP1.05 billion from GBP1.13 billion the prior year, reflecting a drop in value from the Life Sciences and Multi-Sector portions of the portfolio.

As at December 31, IP's portfolio comprises 57 "focus companies" - which represents 87% of its value - and 75 other companies. During the year, the group exited its interest in 8 companies, realising GBP79.5 million in cash proceeds, up from GBP29.5 million in 2018.

IP's portfolio loss for 2019 narrowed to GBP43.9 million from GBP48.4 million, with the major detractors being Autifony Therapeutics Ltd, PsiOxus Therapeutics Ltd and Topivert Ltd.

Positive contributors included Ceres Power Holdings PLC on new product launches and development contracts, while medical analysis firm Oxford Nanopore Technologies Ltd reported a robust 2018, leading to expansion in 2019.

"During 2019 the group's portfolio saw a net fair value reduction of GBP43.9 million or 4%, and, whilst disappointing, this reflects ongoing rationalisation in the portfolio and significant headwinds, particularly in the UK market. However, our three most valuable holdings, Oxford Nanopore, Istesso and Ceres Power, made excellent progress during the year with Oxford Nanopore and Ceres Power also announcing positive developments since the year end," said Chief Executive Alan Aubrey.

"Consequently, we remain confident in the prospects of our portfolio, which we continue to believe includes world-changing businesses that will deliver impact and significant benefits for multiple stakeholders," Aubrey added.

Shares in IP Group were up 1.5% at 59.35 pence on Wednesday in London.

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
27 Jul 2021 12:07

IP Group's Artios raises USD153 million for cancer therapy pipeline

IP Group's Artios raises USD153 million for cancer therapy pipeline

Read more
27 Jul 2021 09:18

IP Group portfolio company completes Series C financing

(Sharecast News) - Intellectual property-based business investor IP Group said on Tuesday that portfolio company Artios Pharma had completed a $153.0m Series C financing to fund the further development of its clinical-stage pipeline.

Read more
28 Jun 2021 13:41

IN BRIEF: IP Group Non-Exec Director Hynes buys 21,000 shares

IN BRIEF: IP Group Non-Exec Director Hynes buys 21,000 shares

Read more
17 Jun 2021 09:48

IP Group investee Apollo Therapeutics completes USD145 million raise

IP Group investee Apollo Therapeutics completes USD145 million raise

Read more
17 Jun 2021 07:40

IP Group portfolio business raises $145m in financing round

(Sharecast News) - Intellectual property business IP Group said on Thursday that portfolio company Apollo Therapeutics had completed a $145.0m financing round.

Read more
9 Jun 2021 16:08

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
9 Jun 2021 14:27

IN BRIEF: IP Group invests GBP250,000 in GBP1.1 million Itaconix raise

IN BRIEF: IP Group invests GBP250,000 in GBP1.1 million Itaconix raise

Read more
9 Jun 2021 09:21

IN BRIEF: IP Group expects GBP80 million in first half realisations

IN BRIEF: IP Group expects GBP80 million in first half realisations

Read more
9 Jun 2021 08:01

IP Group preparing for first divi as portfolio progress continues

(Sharecast News) - Intellectual property business developer IP Group said on Wednesday that for the year to date, its positive progress made by many of its portfolio companies in 2020 had continued.

Read more
7 Jun 2021 09:24

IP Group sells part of Iksuda Therapeutics stake in financing round

IP Group sells part of Iksuda Therapeutics stake in financing round

Read more
7 Jun 2021 07:25

IP Group portfolio co Iksuda raises £42m to develop cancer drug

(Sharecast News) - Intellectual property business developer IP Group said its portfolio company Iksuda Therapeutics had completed a $42m (£29m) financing round to fund human clinical trials of its lead cancer drug.

Read more
2 Jun 2021 15:55

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
28 May 2021 15:12

IP Group launches joint venture aiming to provide capital in China

IP Group launches joint venture aiming to provide capital in China

Read more
27 May 2021 13:25

TRADING UPDATES: Savills brings in Samsung Life as unit investor

TRADING UPDATES: Savills brings in Samsung Life as unit investor

Read more
17 May 2021 14:06

IP Group gains GBP20 million after portfolio company sale

IP Group gains GBP20 million after portfolio company sale

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.